276 related articles for article (PubMed ID: 35798092)
1. Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats.
Mairinger S; Hernández-Lozano I; Filip T; Sauberer M; Löbsch M; Stanek J; Wanek T; Sake JA; Pekar T; Ehrhardt C; Langer O
J Control Release; 2022 Sep; 349():109-117. PubMed ID: 35798092
[TBL] [Abstract][Full Text] [Related]
2. Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice.
Biali ME; Auvity S; Cisternino S; Smirnova M; Hacker M; Zeitlinger M; Mairinger S; Tournier N; Bauer M; Langer O
Mol Pharm; 2023 Nov; 20(11):5877-5887. PubMed ID: 37883694
[TBL] [Abstract][Full Text] [Related]
3. Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of 11C-Erlotinib.
Traxl A; Wanek T; Mairinger S; Stanek J; Filip T; Sauberer M; Müller M; Kuntner C; Langer O
J Nucl Med; 2015 Dec; 56(12):1930-6. PubMed ID: 26359257
[TBL] [Abstract][Full Text] [Related]
4. PET imaging to assess the impact of P-glycoprotein on pulmonary drug delivery in rats.
Hernández-Lozano I; Mairinger S; Filip T; Sauberer M; Wanek T; Stanek J; Sake JA; Pekar T; Ehrhardt C; Langer O
J Control Release; 2022 Feb; 342():44-52. PubMed ID: 34971693
[TBL] [Abstract][Full Text] [Related]
5. Influence of P-glycoprotein on pulmonary disposition of the model substrate [
Mairinger S; Hernández-Lozano I; Filip T; Löbsch M; Stanek J; Zeitlinger M; Hacker M; Tournier N; Wanek T; Ehrhardt C; Langer O
Eur J Pharm Sci; 2023 Apr; 183():106404. PubMed ID: 36773747
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [
Traxl A; Mairinger S; Filip T; Sauberer M; Stanek J; Poschner S; Jäger W; Zoufal V; Novarino G; Tournier N; Bauer M; Wanek T; Langer O
Mol Pharm; 2019 Mar; 16(3):1282-1293. PubMed ID: 30694684
[TBL] [Abstract][Full Text] [Related]
7. (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.
Liow JS; Zoghbi SS; Hu S; Hall MD; Hines CS; Shetty HU; Araneta MD; Page EM; Pike VW; Kreisl WC; Herscovitch P; Gottesman MM; Theodore WH; Innis RB
Neuroimage; 2016 Sep; 138():134-140. PubMed ID: 27211474
[TBL] [Abstract][Full Text] [Related]
8. A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier.
Wanek T; Kuntner C; Bankstahl JP; Mairinger S; Bankstahl M; Stanek J; Sauberer M; Filip T; Erker T; Müller M; Löscher W; Langer O
J Cereb Blood Flow Metab; 2012 Nov; 32(11):2002-11. PubMed ID: 22828996
[TBL] [Abstract][Full Text] [Related]
9. Functional Evaluation of P-gp and Bcrp at the Murine Blood-Cerebrospinal Fluid Barrier.
Sun A; Wang J
Pharm Res; 2023 Nov; 40(11):2667-2675. PubMed ID: 37704894
[TBL] [Abstract][Full Text] [Related]
10. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
[TBL] [Abstract][Full Text] [Related]
11. Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier.
Bauer M; Karch R; Zeitlinger M; Stanek J; Philippe C; Wadsak W; Mitterhauser M; Jäger W; Haslacher H; Müller M; Langer O
J Nucl Med; 2013 Aug; 54(8):1181-7. PubMed ID: 23833270
[TBL] [Abstract][Full Text] [Related]
12. The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).
Kannan P; Telu S; Shukla S; Ambudkar SV; Pike VW; Halldin C; Gottesman MM; Innis RB; Hall MD
ACS Chem Neurosci; 2011 Feb; 2(2):82-9. PubMed ID: 22778859
[TBL] [Abstract][Full Text] [Related]
13. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
[TBL] [Abstract][Full Text] [Related]
14. [(18)F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent blood-brain barrier.
Wanek T; Traxl A; Bankstahl JP; Bankstahl M; Sauberer M; Langer O; Kuntner C
Nucl Med Biol; 2015 Jul; 42(7):585-9. PubMed ID: 25823393
[TBL] [Abstract][Full Text] [Related]
15. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
Römermann K; Wanek T; Bankstahl M; Bankstahl JP; Fedrowitz M; Müller M; Löscher W; Kuntner C; Langer O
Nucl Med Biol; 2013 Oct; 40(7):873-8. PubMed ID: 23845421
[TBL] [Abstract][Full Text] [Related]
16. Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice.
Mairinger S; Zoufal V; Wanek T; Traxl A; Filip T; Sauberer M; Stanek J; Kuntner C; Pahnke J; Müller M; Langer O
Eur J Pharm Sci; 2018 Mar; 115():212-222. PubMed ID: 29360507
[TBL] [Abstract][Full Text] [Related]
17. Assessing the Functional Redundancy between P-gp and BCRP in Controlling the Brain Distribution and Biliary Excretion of Dual Substrates with PET Imaging in Mice.
Hernández-Lozano I; Mairinger S; Traxl A; Sauberer M; Filip T; Stanek J; Kuntner C; Wanek T; Langer O
Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452247
[TBL] [Abstract][Full Text] [Related]
18. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
Marchetti S; de Vries NA; Buckle T; Bolijn MJ; van Eijndhoven MA; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
Mol Cancer Ther; 2008 Aug; 7(8):2280-7. PubMed ID: 18723475
[TBL] [Abstract][Full Text] [Related]
19. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
[TBL] [Abstract][Full Text] [Related]
20. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.
de Vries NA; Buckle T; Zhao J; Beijnen JH; Schellens JH; van Tellingen O
Invest New Drugs; 2012 Apr; 30(2):443-9. PubMed ID: 20963470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
